

# Most Cost-Effective Setting Program Drug List

Established in 2012, the Most Cost-Effective Setting (MCES) Program requires that Independence Blue Cross (Independence) approve the treatment setting for certain medications eligible for coverage under the Independence medical benefit.

The main goal of the MCES Program is to manage the total cost of care by ensuring that members meet the coverage criteria in our medical policy, and that the requested treatment setting for these members is both safe and cost-effective. This review is conducted as part of the precertification process for members enrolled in Commercial medical plans.

Drug	Date Added to Program
Actemra®	September 1, 2017
Adagen®	October 1, 2018
Aralast NP®	July 1, 2012
Benlysta®	June 1, 2018
Bivigam®	January 1, 2012*
Carimune® NF	January 1, 2012*
Cerezyme®	January 1, 2012
Crysvita®	October 1, 2018
Cutaquig®	January 1, 2012*
Cuvitru™	January 1, 2012*
Elelyso™	July 1, 2012
Entyvio®	September 1, 2017
Exondys-51™	January 1, 2017
Fabrazyme®	July 1, 2012
Flebogamma®	January 1, 2012*
Flebogamma® DIF	January 1, 2012*
Fulphila™	June 25, 2018
Gamastan® S/D	January 1, 2012*
Gamifant®	November 20, 2018
Gammagard® Liquid	January 1, 2012*
Gammagard® S/D	January 1, 2012*
Gammaked™	January 1, 2012*
Gammaplex®	January 1, 2012*
Gamunex® C	January 1, 2012*
Glassia®	July 1, 2012
Hizentra®	January 1, 2012*
HyQvia®	January 1, 2012*
Ilaris®	January 1, 2019
Ilumya™	November 1, 2018
Inflectra®	September 1, 2017
Ixifi™	June 1, 2018

Drug	Date Added to Program
Kanuma <sup>®</sup>	November 1, 2018
Lumizyme <sup>®</sup>	July 1, 2012
Naglazyme <sup>®</sup>	October 1, 2018
Neulasta <sup>®</sup>	January 1, 2017
Neulasta <sup>®</sup> Onpro <sup>®</sup>	January 1, 2017
Nucala <sup>®</sup>	January 1, 2018
Ocrevus <sup>™</sup>	January 1, 2018
Octagam <sup>®</sup>	January 1, 2012*
Onpattro <sup>™</sup>	August 10, 2018
Orencia <sup>®</sup>	September 1, 2017
Panzyga <sup>®</sup>	January 1, 2012*
Privigen <sup>®</sup>	January 1, 2012*
Prolastin <sup>®</sup>	July 1, 2012
Prolia <sup>®</sup>	July 1, 2013
Radicava <sup>™</sup>	January 1, 2018
Remicade <sup>®</sup>	September 1, 2017
Renflexis <sup>®</sup>	September 1, 2017
Revcovi <sup>™</sup>	November 1, 2018
Sandostatin <sup>®</sup> LAR depot	January 1, 2017
Simponi Aria <sup>®</sup>	September 1, 2017
Soliris <sup>®</sup>	January 1, 2012
Somatuline <sup>®</sup> depot	January 1, 2018
Stelara <sup>®</sup>	July 1, 2013
Udenyca <sup>™</sup>	November 2, 2018
Ultomiris <sup>™</sup>	December 21, 2018
Vimizim <sup>®</sup>	August 1, 2014
VPRIV <sup>®</sup>	January 1, 2012
Xolair <sup>®</sup>	July 1, 2013
Zemaira <sup>®</sup>	July 1, 2012

This list is subject to change. All biosimilars to an originator product in this program are subject to precertification review for most cost-effective setting.

\*The intravenous/subcutaneous immunoglobulin (IVIG/SCIG) class of drugs was added to the Most Cost-Effective Setting Program on January 1, 2012. Some drugs in this class were approved by the U.S. Food and Drug Administration after this date, but they reflect the January 1, 2012 date to indicate when program requirements went into effect for all drugs in that class.



Independence Blue Cross offers products through its subsidiaries Independence Hospital Indemnity Plan, Keystone Health Plan East and QCC Insurance Company, and with Highmark Blue Shield — independent licensees of the Blue Cross and Blue Shield Association.